The Role of Hyperthermic Intraperitoneal Chemotherapy in Uterine Cancer Therapy.
Female
Humans
Combined Modality Therapy
Hyperthermic Intraperitoneal Chemotherapy
Hyperthermia, Induced
Peritoneal Neoplasms
/ drug therapy
Uterine Neoplasms
/ drug therapy
Endometrial Neoplasms
/ pathology
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Sarcoma
/ drug therapy
Survival Rate
Retrospective Studies
cancer
chemotherapy
endometrial
hyperthermic
intraperitoneal
sarcoma
uterine
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
02 Aug 2023
02 Aug 2023
Historique:
received:
16
07
2023
revised:
28
07
2023
accepted:
30
07
2023
medline:
14
8
2023
pubmed:
12
8
2023
entrez:
12
8
2023
Statut:
epublish
Résumé
Endometrial cancer and uterine sarcoma represent the two major types of uterine cancer. In advanced stages, both cancer entities are challenging to treat and correlate with a meagre survival and prognosis. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is a form of localized chemotherapy that is heated to improve the chemotherapeutic effect on peritoneal metastases. The aim of the current review is to study the role of HIPEC in the treatment of uterine cancer. A literature review was conducted using the MEDLINE and LIVIVO databases with a view to identifying relevant studies. By employing the search terms "hyperthermic intraperitoneal chemotherapy", "uterine cancer", "endometrial cancer", and/or "uterine sarcoma", we managed to identify 26 studies published between 2004 and 2023. The present work embodies the most up-to-date, comprehensive review of the literature centering on the particular role of HIPEC as treatment modality for peritoneally metastasized uterine cancer. Patients treated with cytoreductive surgery, alongside HIPEC, seem to profit from not only higher survival but also lower recurrence rates. Factors such as the completeness of cytoreductive surgery, the peritoneal cancer index, the histologic subtype, or the applied chemotherapeutic agent, all influence HIPEC therapy effectiveness. In summary, HIPEC seems to represent a promising treatment alternative for aggressive uterine cancer.
Identifiants
pubmed: 37569726
pii: ijms241512353
doi: 10.3390/ijms241512353
pmc: PMC10419250
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Gynecol Oncol. 2021 Feb;160(2):364-368
pubmed: 33419611
Cancers (Basel). 2021 Jun 22;13(13):
pubmed: 34206563
Surg Oncol. 2020 Jun;33:19-23
pubmed: 32561085
Int J Mol Sci. 2023 May 24;24(11):
pubmed: 37298140
Ann Surg Oncol. 2014 Mar;21(3):908-14
pubmed: 24276642
Crit Rev Oncol Hematol. 2018 Feb;122:10-20
pubmed: 29458779
Int J Gynecol Cancer. 2007 Jan-Feb;17(1):204-9
pubmed: 17291254
Gynecol Minim Invasive Ther. 2021 Aug 03;10(3):191-194
pubmed: 34485069
Pleura Peritoneum. 2017 Sep 01;2(3):129-136
pubmed: 30911642
Anticancer Res. 2013 Mar;33(3):1041-4
pubmed: 23482779
Ann Surg Oncol. 2010 Dec;17(12):3220-8
pubmed: 20585874
Int J Gynecol Cancer. 2010 Jul;20(5):809-14
pubmed: 20973274
Hum Pathol. 1995 Nov;26(11):1268-74
pubmed: 7590703
Georgian Med News. 2021 Nov;(320):37-41
pubmed: 34897042
Am J Obstet Gynecol. 2014 Mar;210(3):259.e1-8
pubmed: 24211479
Eur J Obstet Gynecol Reprod Biol. 2014 Jan;172:111-4
pubmed: 24300558
J Chemother. 2004 Nov;16 Suppl 5:19-22
pubmed: 15675470
Clin Case Rep. 2018 May 02;6(6):1142-1152
pubmed: 29881584
BMC Surg. 2022 Jan 7;22(1):1
pubmed: 34996419
Gynecol Oncol Rep. 2015 Jul 02;13:60-3
pubmed: 26425725
Gynecol Oncol. 2007 May;105(2):493-500
pubmed: 17303224
J Surg Oncol. 2022 Jun;125(7):1176-1182
pubmed: 35481913
Gynecol Oncol Rep. 2021 Mar 04;36:100741
pubmed: 33748383
JAMA Oncol. 2021 Aug 01;7(8):1231-1238
pubmed: 33956063
A A Pract. 2020 Jan 1;14(1):1-5
pubmed: 31651415
Dis Markers. 2021 Nov 12;2021:7850688
pubmed: 34804263
Indian J Surg Oncol. 2016 Jun;7(2):152-9
pubmed: 27065705
Cancers (Basel). 2022 Jul 20;14(14):
pubmed: 35884577
J Pers Med. 2022 Oct 30;12(11):
pubmed: 36579503
Int J Surg Case Rep. 2019;64:10-14
pubmed: 31590134
J BUON. 2012 Jul-Sep;17(3):522-5
pubmed: 23033293
Oncologist. 2016 Oct;21(10):1250-1259
pubmed: 27412393
Int J Mol Med. 2007 Feb;19(2):301-8
pubmed: 17203205
Medeni Med J. 2020;35(3):202-211
pubmed: 33110672
J Obstet Gynaecol Can. 2021 Feb;43(2):247-250
pubmed: 33039314
Med Int (Lond). 2023 May 04;3(3):25
pubmed: 37205988
Int J Gynecol Cancer. 2018 Jul;28(6):1130-1137
pubmed: 29975291
Ann Saudi Med. 2014 Mar-Apr;34(2):159-66
pubmed: 24894786
Int J Gynecol Cancer. 2021 Jan;31(1):12-39
pubmed: 33397713
Eur Rev Med Pharmacol Sci. 2018 Feb;22(4):950-960
pubmed: 29509243
Anticancer Res. 2022 Jul;42(7):3681-3692
pubmed: 35790287
Eur J Surg Oncol. 2017 Nov;43(11):2170-2177
pubmed: 28967566
Gynecol Oncol Rep. 2021 Oct 15;38:100876
pubmed: 34761096
J BUON. 2008 Apr-Jun;13(2):205-10
pubmed: 18555466
Ann Surg Oncol. 2016 May;23(5):1501-7
pubmed: 26545375
Ann Surg Oncol. 2018 Mar;25(3):679-687
pubmed: 29282600
Obstet Gynecol Int. 2010;2010:923824
pubmed: 20169171
Acta Oncol. 2012 Jul;51(6):694-705
pubmed: 22793037
ESMO Open. 2022 Oct;7(5):100586
pubmed: 36116421